Retinal atrophy is the progressive, irreversible loss of functional cells in the retina, the light-sensitive tissue lining the back of your eye. The most common form in adults is geographic atrophy, a late stage of dry age-related macular degeneration, but inherited gene mutations, blood vessel blockages, certain medications, and autoimmune conditions can also destroy retinal tissue. Because the retina cannot regenerate its specialized cells once they die, the central challenge of retinal atrophy is that vision loss tends to be permanent, though the speed and pattern of that loss vary enormously depending on the cause.
What Actually Breaks Down
The retina is a layered structure. Its outermost layer, the retinal pigment epithelium (RPE), sits beneath the photoreceptors (rods and cones) and keeps them alive by recycling waste, delivering nutrients, and absorbing excess light. When RPE cells die, the photoreceptors they support die shortly after, and the blood vessel layer underneath (the choriocapillaris) can deteriorate as well. That chain reaction is the core of retinal atrophy regardless of what triggered it.
RPE cells are especially vulnerable to oxidative stress. When oxidative damage overwhelms the cell’s repair systems, phagocytosis and autophagy break down, and the cell dies. Research shows this death is often necrotic rather than apoptotic: experiments on RPE cells found no signs of classic programmed cell death such as DNA fragmentation or caspase activation, but instead saw ATP depletion, membrane breakdown, and aggregation of a protein called RIPK3, all hallmarks of necrosis. Blocking that protein largely prevented the cells from dying.
1Cell Death & Disease. Induction of necrotic cell death by oxidative stress in retinal pigment epithelial cellsThis matters because necrotic cell death spills inflammatory contents into surrounding tissue, potentially accelerating damage to neighboring cells. Apoptosis and endoplasmic reticulum stress also contribute in some retinal degenerative diseases, so the picture is not exclusively necrotic, but the necrotic pathway appears to play a larger role in RPE loss than researchers once assumed.
2Frontiers in Pharmacology. Functions and Diseases of the Retinal Pigment EpitheliumAge-Related Macular Degeneration and Geographic Atrophy
By far the most common cause of retinal atrophy in adults is geographic atrophy (GA), a late-stage complication of dry age-related macular degeneration. GA involves the death of RPE, photoreceptors, and choriocapillaris in well-defined patches that gradually expand. The underlying trigger is chronic inflammation driven by overactivation of the complement system, part of the body’s innate immune defense.
3PubMed Central. Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement systemComplement proteins are supposed to tag and destroy invaders, then shut off. In people with certain genetic risk factors, the off switch is faulty. Complement stays active, attacking healthy retinal tissue year after year. Multiple studies have found complement proteins, age-dependent increases in complement gene expression, and accumulation of the membrane attack complex in retinas affected by GA.
4Eye. Complement cascade inhibition in geographic atrophy: a reviewEnvironmental and cumulative damage from aging, UV exposure, and other stressors feeds into this cycle, and when complement regulation is compromised, the inflammation becomes self-sustaining.
5PubMed Central. The Pathophysiology of Geographic Atrophy Secondary to Age-Related Macular Degeneration and the Complement Pathway as a Therapeutic TargetInherited Retinal Dystrophies
Not all retinal atrophy is age-related. Dozens of gene mutations can cause the retina to degenerate during childhood, adolescence, or early adulthood. The ABCA4 gene is one of the best-studied examples. Mutations in this gene are responsible for Stargardt disease, the most common inherited macular dystrophy in young people, as well as cone-rod dystrophy and some forms of retinitis pigmentosa. The severity depends on how much function the mutated protein retains: mild loss of function tends to produce Stargardt disease, moderate loss causes cone-rod dystrophy, and near-total loss causes a picture resembling retinitis pigmentosa.
6Ophthalmology. Three families displaying the combination of Stargardt’s disease with cone–rod dystrophy or retinitis pigmentosaEven within a single family carrying the same mutations, the clinical picture can differ. In one documented Spanish family, one sibling had a Stargardt phenotype driven by ABCA4 mutations while the other had autosomal recessive retinitis pigmentosa caused by mutations in a different gene, CRB1.
7PubMed Central. Molecular analysis of ABCA4 and CRB1 genes in a Spanish family segregating both Stargardt disease and autosomal recessive retinitis pigmentosaRetinitis pigmentosa itself encompasses a large group of conditions in which rod photoreceptors die first, causing night blindness and tunnel vision before central vision narrows. The rate of decline varies wildly: some people maintain functional vision into their sixties while others are legally blind by thirty, depending on the specific mutation and other genetic modifiers.
Other Causes
Several non-genetic, non-age-related pathways can also lead to retinal atrophy.
- High myopia: Severe nearsightedness stretches the eyeball, thinning the retina and choroid. Pathologic myopia is defined by characteristic complications in the back of the eye, including posterior staphyloma or myopic maculopathy at or beyond the level of diffuse choroidal atrophy. 8PubMed Central. IMI Pathologic Myopia
- Vascular occlusion: When a retinal artery becomes blocked, the inner retinal layers swell acutely; over time, those ischemic changes resolve into permanent inner retinal atrophy visible on imaging. 9Retina. IN VIVO DETECTION OF ACUTE ISCHEMIC DAMAGES IN RETINAL ARTERIAL OCCLUSION WITH OPTICAL COHERENCE TOMOGRAPHY
- Medications: Certain drugs are toxic to the RPE with prolonged use. Hydroxychloroquine, widely prescribed for lupus and rheumatoid arthritis, is the best-known culprit. More recently, pentosan polysulfate sodium, a bladder medication, has been linked to a distinctive pattern of macular damage, and concurrent hydroxychloroquine use may increase the risk. 10PubMed Central. Advanced pentosan polysulfate sodium maculopathy with low cumulative exposure and hydroxychloroquine use
- Autoimmune retinopathy: Autoantibodies targeting retinal proteins can cause widespread retinal atrophy. The fundus may initially look normal, but imaging and testing reveal diffuse atrophy in the majority of patients, RPE changes, and sometimes macular edema.
11PubMed Central. Autoimmune Retinopathy
What You Notice First
The earliest symptom of retinal atrophy depends on which part of the retina is affected. When atrophy begins outside the fovea (the center of the macula responsible for sharp reading vision), you may not notice anything at all for months or even years. Peripheral atrophy, as in early retinitis pigmentosa, often announces itself as difficulty seeing in dim light or bumping into objects at the edges of your visual field.
When the macula is involved, the signs become harder to ignore. Straight lines may appear wavy or bent, colors may look washed out, and a blurry or dark patch may develop near the center of your vision. In geographic atrophy, the atrophic patches often start around the fovea and spread inward, so central reading vision can be spared early on while you struggle with contrast and dim lighting. Eventually, lesions reach the fovea. A real-world registry study found that roughly 8 percent of eyes with geographic atrophy in both eyes progressed from non-subfoveal to subfoveal involvement within twelve months, and about 13 percent by two years.
12Ophthalmology Science. Natural History of Geographic Atrophy in Real-World Clinical Practice: Results from the IRIS RegistryOnce the fovea is involved, measurable vision loss accelerates. Data from clinical trials in geographic atrophy showed that roughly three-quarters of eyes lost at least one line on an eye chart within two years, and about a quarter lost three or more lines in that time.
13Ophthalmology. Visual Loss in Geographic Atrophy: Learnings from the Lampalizumab TrialsHow Retinal Atrophy Is Diagnosed
A standard dilated eye exam can reveal obvious atrophic patches, but modern imaging has made it possible to detect retinal atrophy much earlier and to track its growth precisely.
Optical coherence tomography (OCT) is the workhorse. It produces cross-sectional images of the retina at near-microscopic resolution, letting clinicians see thinning, loss of the RPE layer, and disruption of the photoreceptor layers. Recent work refining the definition of early atrophic lesions found that certain OCT features, especially choroidal hypertransmission (light passing through where the RPE should block it) and complete RPE loss, strongly predict deep visual sensitivity defects, with over 90 percent of lesions showing both features associated with repeatable, severe sensitivity loss.
14Ophthalmology Science. Defining Atrophic Age-Related Macular Lesions Associated with Repeatable Deep Visual Sensitivity DefectsInterreader agreement among trained graders is generally good for most OCT features of atrophy, though some subtle findings like RPE disruption are harder for readers to agree on.
15Ophthalmology Retina. OCT Signs of Early Atrophy in Age-Related Macular Degeneration: Interreader AgreementFundus autofluorescence (FAF) is a complementary technique. It maps a waste product called lipofuscin that builds up in RPE cells as they struggle to process photoreceptor debris. Areas of intense autofluorescence suggest stressed, overloaded RPE, while dark zones where autofluorescence has disappeared mark areas where the RPE has already died. This pattern is useful for tracking how fast atrophic patches are expanding.
16Retina. FUNDUS AUTOFLUORESCENCE IMAGINGElectrophysiology tests such as the electroretinogram (ERG) measure electrical responses from the retina and can reveal widespread functional loss even when imaging looks relatively subtle. In geographic atrophy, the ERG shows specific abnormalities, and late-stage AMD eyes have more diminished cone responses compared with healthy controls and early-stage disease.
17PubMed. Full-field electroretinography in age-related macular degeneration: an overall retinal response In patients with extensive macular atrophy and pseudodrusen, virtually all had abnormalities on the multifocal ERG, and about four in five showed changes on full-field testing.
18PubMed. Electrophysiological findings in extensive macular atrophy with pseudodrusenWhen Atrophy Overlaps with Other Conditions
Retinal atrophy can look similar on imaging to damage from unrelated diseases, making differential diagnosis important. Glaucoma, for instance, is traditionally thought of as a disease of the inner retina and optic nerve, not the photoreceptor layers. But ultrahigh-resolution imaging has revealed outer retinal changes in glaucomatous eyes with visual field loss, blurring the line between glaucoma and retinal degeneration on a scan.
19PubMed. Evidence of outer retinal changes in glaucoma patients as revealed by ultrahigh-resolution in vivo retinal imagingIn children, the overlap is even trickier. A study of pediatric eyes found outer retinal changes in about 13 percent of glaucomatous eyes and 8 percent of eyes with non-glaucomatous optic atrophy, often explained by prior surgery, uveitis, or underlying retinal disease rather than the glaucoma itself.
20American Journal of Ophthalmology. Retinal changes in pediatric eyes with glaucoma and nonglaucomatous optic atrophyLifestyle Factors That Influence Risk and Speed
For age-related forms of retinal atrophy, the two most consistently identified modifiable risk factors are smoking and age itself. Current and former smoking, physical inactivity, prolonged unprotected sun exposure, diabetes, hypertension, cardiovascular disease, and obesity have all been linked to a higher risk of developing or worsening macular degeneration.
21PubMed Central. Modifiable Lifestyle Risk Factors and Strategies for Slowing the Progression of Age-Related Macular DegenerationThe AREDS and AREDS2 trials established that a specific supplement formula containing vitamins C and E, zinc, copper, lutein, and zeaxanthin reduces the risk of progressing from intermediate dry AMD to the wet form. Adherence to a Mediterranean diet has also been associated with lower risk of both early and late AMD. These interventions do not reverse existing atrophy, but they may slow the march toward it.
21PubMed Central. Modifiable Lifestyle Risk Factors and Strategies for Slowing the Progression of Age-Related Macular DegenerationAmong non-modifiable factors, age and genetics are the strongest predictors of progression.
22PubMed Central. Risk factors for progression of age-related macular degenerationTreatment Landscape
For decades there was no approved treatment for geographic atrophy. That changed with complement inhibitors. The rationale is straightforward: if chronic complement activation is fueling the tissue destruction, dampening it should slow the process. While most complement-targeting drugs tested in AMD have failed, two reached phase III clinical trials after demonstrating reduced rates of atrophy growth in phase II.
23PubMed Central. Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic OptionPegcetacoplan and avacincaptad pegol are now approved by the FDA for geographic atrophy. Both are given as eye injections, typically monthly or every other month. They slow the expansion of atrophic lesions but do not restore lost tissue. Patients and physicians weigh the burden of frequent injections against a modest reduction in the rate of worsening, so the decision to start treatment is individualized.
For inherited retinal dystrophies, gene therapy has moved from concept to clinic. The first approved retinal gene therapy targets RPE65-associated retinal dystrophy (a cause of childhood-onset blindness) and delivers a working copy of the gene directly beneath the retina. Preliminary results in other recessive retinal diseases also show promising safety and improved visual function over extended follow-up periods. Stem cell-derived RPE transplantation has also been delivered safely to human eyes, though it remains experimental for most conditions.
24PubMed Central. Gene Therapy and Stem Cell Transplantation in Retinal Disease: The New FrontierLiving with Retinal Atrophy
Because no current treatment can rebuild dead retinal tissue, rehabilitation becomes a practical priority. Low vision rehabilitation includes prescribing magnifying devices, training patients to use eccentric viewing (looking slightly off-center to use healthier retinal areas), and optimizing lighting and contrast at home. In a controlled study of patients with geographic atrophy, those who received formal low vision rehabilitation showed significant improvements in quality-of-life scores covering general vision, near and distance activities, social functioning, mental health, and independence, while a control group showed no improvement on any measure. Nearly all patients were prescribed at least one magnifying aid for near tasks, and about a fifth needed more than one device.
25PubMed Central. Rehabilitation Methods for Patients with Geographic Atrophy due to Age-Related Macular Degeneration and Effects of Rehabilitation on Quality of LifeThe emotional toll deserves attention too. Losing central vision affects reading, driving, recognizing faces, and navigating unfamiliar places. Depression and social withdrawal are common and often under-recognized. Occupational therapists, orientation and mobility specialists, and support groups all play roles that medications and imaging cannot fill.
Artificial Intelligence and Early Detection
One of the more promising recent developments is the use of deep-learning algorithms to predict who is about to develop geographic atrophy before the first lesion appears. A model called DeepGAze, trained on OCT scans, predicted progression from intermediate AMD to geographic atrophy within one year with high accuracy, correctly identifying about 88 percent of eyes that would progress and 90 percent of those that would not.
26JAMA Ophthalmology. A Deep-Learning Algorithm to Predict Short-Term Progression to Geographic Atrophy on Spectral-Domain Optical Coherence TomographyIf tools like this enter routine clinical use, they could change how often at-risk patients are screened and when treatment is started. Right now, complement inhibitors are approved only after atrophy has already formed. Identifying patients at imminent risk of developing it could open a window for preventive intervention, assuming clinical trials eventually test that strategy. For the moment, though, the technology is being validated rather than deployed, and the gap between a good algorithm and a changed clinical workflow remains wide.